Omixon joins Werfen

Combining strengths to drive innovation

The acquisition of Omixon, a company recognized for its innovation in transplant diagnostics, was the highlight of our year in Transplant.

Welcoming approximately fifty new colleagues with invaluable expertise strengthens our ability to expand our portfolio of transplant diagnostics for hospitals and HLA laboratories, allowing us to better support the transplant community worldwide. I am particularly excited about advancing our Next Generation Sequencing (NGS) solutions and the new possibilities Omixon unlocks to enhance our offering for post-transplant monitoring.

This acquisition is a strategic step in expanding our capabilities and proof of our commitment to accelerating innovation in transplant diagnostics. By combining our strengths, we will increase investment in new solutions and enhance our digital capabilities, driving innovations that ultimately improve transplant outcomes.

It also reinforces our dedication to building a stronger Transplant organization. As part of this effort, I have been charged with leading our new structure, strengthening our focus on specialization, which remains central to our mission of advancing patient care.

Our customers will benefit from Omixon’s integration into Werfen as we leverage the potential of both organizations through more investment in our product lines, commercial operations, and internal resources. With our new organization and the skills, commitment, and dedication of our employees, I look forward to delivering innovation and enhanced support to our customers and their patients in 2025 and beyond.